|
G |
Ctbp2 |
C-terminal binding protein 2 |
decreases expression |
ISO |
2-keto-4-methylthiobutyric acid results in decreased expression of CTBP2 protein |
CTD |
PMID:28414304 |
|
NCBI chr 1:187,782,064...187,918,115
Ensembl chr 1:187,782,682...187,920,222
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
2-keto-4-methylthiobutyric acid results in decreased expression of CTNNB1 protein |
CTD |
PMID:28414304 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
affects metabolic processing |
EXP |
KYAT1 protein affects the metabolism of 2-keto-4-methylthiobutyric acid |
CTD |
PMID:2711386 |
|
NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases activity |
ISO |
2-keto-4-methylthiobutyric acid results in decreased activity of ODC1 protein |
CTD |
PMID:16870157 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP ISO |
Aldicarb results in decreased activity of ACHE protein |
CTD |
PMID:8134223 PMID:14644616 PMID:16256972 PMID:21251949 PMID:23962483 PMID:27132127 PMID:33844597 More...
|
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance |
ISO |
APP protein modified form results in decreased susceptibility to Aldicarb |
CTD |
PMID:34902447 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
Aldicarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
Aldicarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Aldicarb inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:9126867 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Il2 |
interleukin 2 |
decreases response to substance |
ISO |
Aldicarb results in decreased susceptibility to IL2 protein |
CTD |
PMID:8349949 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
Aldicarb promotes the reaction [[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in increased expression of MAP2 mRNA] |
CTD |
PMID:32949729 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Nefh |
neurofilament heavy chain |
increases phosphorylation |
ISO |
Aldicarb results in increased phosphorylation of NEFH protein |
CTD |
PMID:16256972 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nrxn1 |
neurexin 1 |
multiple interactions |
ISO |
NRXN1 protein affects the reaction [NLG-1 results in increased susceptibility to Aldicarb]; NRXN1 protein affects the reaction [NRX-1 results in decreased susceptibility to Aldicarb] |
CTD |
PMID:23638761 |
|
NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
|
|
G |
Pax6 |
paired box 6 |
multiple interactions |
ISO |
Aldicarb inhibits the reaction [[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in increased expression of PAX6 mRNA] |
CTD |
PMID:32949729 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Aldicarb inhibits the reaction [Progesterone results in increased activity of PGR protein] |
CTD |
PMID:9126867 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO EXP |
[Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Aldicarb; [Egtazic Acid results in decreased activity of PON1 protein] which results in increased susceptibility to Aldicarb |
CTD |
PMID:27132127 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Vpreb1a |
V-set pre-B cell surrogate light chain 1A |
decreases expression |
ISO |
Aldicarb results in decreased expression of VPREB1 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr11:84,126,969...84,127,846
Ensembl chr11:84,126,969...84,127,846
|
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
EXP |
ametryne results in decreased expression of CDH1 mRNA |
CTD |
PMID:26310382 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
increases expression |
EXP |
ametryne results in increased expression of CDH2 mRNA |
CTD |
PMID:26310382 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases metabolic processing |
ISO |
POR protein promotes the reaction [CYP1A2 protein results in increased metabolism of ametryne] |
CTD |
PMID:8971136 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
ametryne results in decreased expression of GJA1 mRNA |
CTD |
PMID:26310382 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
EXP |
ametryne results in increased expression of GSTM1 mRNA |
CTD |
PMID:26310382 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
POR protein promotes the reaction [CYP1A2 protein results in increased metabolism of ametryne] |
CTD |
PMID:8971136 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
EXP |
ametryne results in increased expression of SOD2 mRNA |
CTD |
PMID:26310382 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
Methiocarb results in decreased activity of ACHE protein |
CTD |
PMID:19934164 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acvr2b |
activin A receptor type 2B |
decreases expression |
EXP |
Methiocarb results in decreased expression of SCGB2A2 mRNA |
CTD |
PMID:15519604 |
|
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
|
|
G |
Alb |
albumin |
increases hydrolysis multiple interactions |
ISO EXP |
ALB protein results in increased hydrolysis of Methiocarb bis(4-nitrophenyl)phosphate inhibits the reaction [ALB protein results in increased hydrolysis of Methiocarb] |
CTD |
PMID:27665777 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO EXP |
Dihydrotestosterone inhibits the reaction [Methiocarb results in increased activity of AR protein]; Methiocarb inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; Methiocarb inhibits the reaction [Metribolone results in increased activity of AR protein] Methiocarb inhibits the reaction [Metribolone results in increased expression of AR mRNA] |
CTD |
PMID:15064155 PMID:15519604 PMID:18324785 PMID:21310686 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
[Carbaryl co-treated with Propoxur co-treated with Methiocarb co-treated with Methomyl co-treated with formetanate co-treated with oxamyl co-treated with Carbofuran] affects the activity of BCHE protein |
CTD |
PMID:22649187 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases metabolic processing |
ISO |
[CYP2B6 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases metabolic processing multiple interactions |
ISO |
CYP2C19 protein results in increased metabolism of Methiocarb [CYP2C19 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing multiple interactions |
ISO |
CYP2D6 protein results in increased metabolism of Methiocarb [CYP2D6 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Esr1 |
estrogen receptor 1 |
increases activity increases expression |
ISO |
Methiocarb results in increased activity of ESR1 protein Methiocarb results in increased expression of ESR1 protein |
CTD |
PMID:15064155 PMID:19206145 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases activity increases expression |
ISO |
Methiocarb results in increased activity of ESR2 protein Methiocarb results in increased expression of ESR2 mRNA |
CTD |
PMID:15064155 PMID:15130599 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions increases metabolic processing |
ISO |
[FMO1 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide |
CTD |
PMID:27665777 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Il2 |
interleukin 2 |
decreases response to substance |
ISO |
Methiocarb results in decreased susceptibility to IL2 protein |
CTD |
PMID:8349949 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
Methiocarb results in decreased expression of LHB protein |
CTD |
PMID:15519604 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
EXP |
Methiocarb results in increased activity of NR1I2 protein |
CTD |
PMID:27665777 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
decreases expression |
EXP |
Methiocarb results in decreased expression of ODC1 mRNA |
CTD |
PMID:15519604 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases activity |
EXP |
Methiocarb results in increased activity of PPARA protein |
CTD |
PMID:27665777 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Methiocarb binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:26359731 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO EXP |
methamidophos promotes the reaction [Methomyl results in decreased activity of ACHE protein]; Methomyl promotes the reaction [methamidophos results in decreased activity of ACHE protein] |
CTD |
PMID:8134223 PMID:19371631 PMID:19934164 PMID:21251949 PMID:23962483 PMID:25707986 PMID:33844597 More...
|
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Methomyl results in increased expression of BAX mRNA |
CTD |
PMID:34676817 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
[Carbaryl co-treated with Propoxur co-treated with Methiocarb co-treated with Methomyl co-treated with formetanate co-treated with oxamyl co-treated with Carbofuran] affects the activity of BCHE protein |
CTD |
PMID:22649187 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Methomyl results in decreased expression of BCL2 mRNA |
CTD |
PMID:34676817 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
Methomyl results in increased expression of CASP3 mRNA |
CTD |
PMID:34676817 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity |
ISO |
Methomyl results in increased activity of CYP19A1 protein |
CTD |
PMID:11884232 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Methomyl inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:9126867 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
EXP |
Methomyl results in increased expression of FSHB protein |
CTD |
PMID:11516254 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression |
ISO |
Methomyl results in decreased expression of HSP90B1 protein |
CTD |
PMID:16271832 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
Methomyl results in decreased expression of HSPA1A protein |
CTD |
PMID:16271832 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
Methomyl results in increased expression of HSPA5 protein |
CTD |
PMID:16271832 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
ISO |
Methomyl results in decreased expression of HSPA8 protein |
CTD |
PMID:16271832 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Kyat1 |
kynurenine aminotransferase 1 |
decreases activity |
ISO |
Methomyl results in decreased activity of KYAT1 protein |
CTD |
PMID:7175100 |
|
NCBI chr 3:13,459,598...13,493,308
Ensembl chr 3:13,459,591...13,493,355
|
|
G |
Kynu |
kynureninase |
decreases activity |
ISO |
Methomyl results in decreased activity of KYNU protein |
CTD |
PMID:7175100 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
EXP |
Methomyl results in increased expression of LHB protein |
CTD |
PMID:11516254 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Methomyl inhibits the reaction [Progesterone results in increased activity of PGR protein] |
CTD |
PMID:9126867 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Prl |
prolactin |
increases expression |
EXP |
Methomyl results in increased expression of PRL protein |
CTD |
PMID:11516254 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
S100a1 |
S100 calcium binding protein A1 |
multiple interactions |
EXP |
Methomyl results in increased expression of and affects the localization of S100A1 protein |
CTD |
PMID:30472887 |
|
NCBI chr 2:175,993,922...175,998,765
Ensembl chr 2:175,993,922...175,999,544
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
increases expression |
EXP |
Methomyl results in increased expression of TPT1 protein |
CTD |
PMID:30472887 |
|
NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625
|
|
|
G |
Glud1 |
glutamate dehydrogenase 1 |
decreases activity |
EXP |
N-acetylmethionine results in decreased activity of GLUD1 protein |
CTD |
PMID:37871522 |
|
NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957
|
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
neticonazole affects the localization of and results in increased activity of NR1I3 protein |
CTD |
PMID:30247703 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein] Pergolide inhibits the reaction [Levodopa results in increased expression of BAX protein] |
CTD |
PMID:15081873 PMID:15672541 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein] |
CTD |
PMID:15081873 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Drd1 |
dopamine receptor D1 |
increases activity |
ISO |
Pergolide results in increased activity of DRD1 protein |
CTD |
PMID:16129789 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
increases activity |
ISO |
Pergolide results in increased activity of DRD2 protein |
CTD |
PMID:16129789 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression increases secretion |
ISO |
Pergolide results in increased expression of GDNF mRNA Pergolide results in increased secretion of GDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
decreases activity |
ISO |
Pergolide results in decreased activity of KCNA5 protein |
CTD |
PMID:16129789 |
|
NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
decreases activity |
EXP |
Pergolide results in decreased activity of KCNMA1 protein |
CTD |
PMID:16129789 |
|
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
|
|
G |
Msh2 |
mutS homolog 2 |
multiple interactions |
ISO |
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein] |
CTD |
PMID:15081873 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Pergolide inhibits the reaction [Hydrogen Peroxide affects the localization of NFKB1 protein]; Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of NFKB1 protein] |
CTD |
PMID:15081873 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Ngf |
nerve growth factor |
increases expression increases secretion |
ISO |
Pergolide results in increased expression of NGF mRNA Pergolide results in increased secretion of NGF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Pergolide inhibits the reaction [Hydrogen Peroxide affects the localization of RELA protein]; Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of RELA protein] |
CTD |
PMID:15081873 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Pergolide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein]; Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein]; Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein]; Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] Pergolide inhibits the reaction [Levodopa results in increased expression of TRP53 protein] |
CTD |
PMID:15081873 PMID:15672541 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Prometryne binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:21115097 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
multiple interactions |
ISO |
S-methyl glutathione inhibits the reaction [ADH5 protein results in increased reduction of S-Nitrosoglutathione] |
CTD |
PMID:19428350 |
|
NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
S-methyl glutathione inhibits the reaction [chelerythrine results in increased cleavage of CASP3 protein] |
CTD |
PMID:26124276 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
saroglitazar inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein] |
CTD |
PMID:32613381 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Elovl6 |
ELOVL fatty acid elongase 6 |
multiple interactions |
ISO |
saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein] |
CTD |
PMID:32613381 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein] |
CTD |
PMID:32613381 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
saroglitazar inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:32613381 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of CPT1A mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of ELOVL6 mRNA]; saroglitazar affects the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] affects the expression of SCD mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in decreased expression of CD36 mRNA]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CCL2 protein]; saroglitazar inhibits the reaction [[osteum co-treated with Palmitic Acid co-treated with Glucose co-treated with INS protein co-treated with TNF protein co-treated with IL1B protein co-treated with TNF protein] results in increased secretion of CXCL5 protein] |
CTD |
PMID:32613381 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO |
CYP1A2 protein results in increased metabolism of terbutryne POR protein promotes the reaction [CYP1A2 protein results in increased metabolism of terbutryne] |
CTD |
PMID:8971136 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
terbutryne binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:20024649 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
POR protein promotes the reaction [CYP1A2 protein results in increased metabolism of terbutryne] |
CTD |
PMID:8971136 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO EXP |
thiodicarb results in decreased activity of ACHE protein |
CTD |
PMID:21251949 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|